SELLAS Life Sciences

SELLAS is right on the doorstep of a make-or-break study result. As of May 2026, its lead cancer trial had recorded 78 of the 80 patient events needed to trigger the final analysis, which means the answer could land at almost any time. In an earlier version of this treatment, patients lived a median of 21 months versus about 5 months on standard care, so a strong confirming result could be worth a fortune.

For a company this small and this early, the balance sheet is unusually strong. SELLAS ended the first quarter of 2026 with 107 million dollars in cash and pulled in millions more afterward, giving it roughly three to four years of runway at its current burn rate of about nine million dollars a quarter. It also has a second drug, SLS009, with its own data readout expected by the end of 2026.

This is one of the most binary bets you can make. The company is valued around 2.7 billion dollars, yet it earns no product revenue and everything hinges on that single trial result. If the study disappoints, the stock could fall more than 70 percent, potentially back toward its cash value of under one dollar a share. There is no soft landing here.

SELLAS loses money every quarter, posting a net loss of 8.4 million dollars in the first quarter of 2026 with no revenue coming in. To stay funded it keeps issuing new stock, and its share count has more than doubled in about a year to over 181 million shares, which shrinks every existing investor's slice. It also has room to sell up to 150 million dollars more in stock whenever it chooses.